Advancing a New Treatment Path for Gout featuring James Mackay

In this episode of The Connect Current, we sit down with James Mackay, Ph.D., President and CEO of Crystalys Therapeutics, to explore how the company is advancing a new treatment path for people living with gout. James shares how Crystalys is developing dotinurad, a next-generation, once-daily oral URAT1 inhibitor, and what the company’s recent $130 million Series B financing enables as it moves through late-stage global clinical development and commercialization preparation. The conversation dives into why gout remains an underserved treatment area, what it takes to execute at this stage of biotech development, and how experienced leadership, strong science, and committed capital can help move promising therapies closer to patients. Recorded at Kiln Rancho Bernardo:https://kiln.com/communities/rancho-bernardo/ Learn more about Crystalys Therapeutics:https://crystalystx.com/